{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T12:03:45Z","timestamp":1781697825570,"version":"3.54.5"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,28]],"date-time":"2025-11-28T00:00:00Z","timestamp":1764288000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,1,3]],"date-time":"2026-01-03T00:00:00Z","timestamp":1767398400000},"content-version":"vor","delay-in-days":36,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"National Key Research and Development Program of China","award":["2021YFA1101501"],"award-info":[{"award-number":["2021YFA1101501"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Nanobiotechnol"],"DOI":"10.1186\/s12951-025-03801-4","type":"journal-article","created":{"date-parts":[[2025,11,28]],"date-time":"2025-11-28T11:17:25Z","timestamp":1764328645000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Improving T cell expansion by optogenetically engineered bacteria-loaded MMP-2-responsive cyclophosphamide for antitumor immunotherapy"],"prefix":"10.1186","volume":"24","author":[{"given":"Jiawen","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renjiang","family":"Kong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuzhi","family":"Qiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sihan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yidi","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xi","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiangliang","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanhong","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,28]]},"reference":[{"key":"3801_CR1","doi-asserted-by":"publisher","first-page":"1652","DOI":"10.1016\/j.cell.2023.03.006","volume":"186","author":"P Sharma","year":"2023","unstructured":"Sharma P, Goswami S, Raychaudhuri D, Siddiqui BA, Singh P, Nagarajan A, et al. Immune checkpoint therapy\u2014current perspectives and future directions. Cell. 2023;186:1652\u201369.","journal-title":"Cell"},{"key":"3801_CR2","doi-asserted-by":"crossref","unstructured":"Iranzo P, Callejo A, Assaf JD, Molina G, Lopez DE, Garcia-Illescas D, et al. Overview of checkpoint inhibitors mechanism of action: role of immune-related adverse events and their treatment on progression of underlying cancer. Front Med. 2022;9;875974.","DOI":"10.3389\/fmed.2022.875974"},{"key":"3801_CR3","doi-asserted-by":"publisher","first-page":"2186","DOI":"10.1038\/s41590-024-02015-4","volume":"25","author":"S Goswami","year":"2024","unstructured":"Goswami S, Pauken KE, Wang L, Sharma P. Next-generation combination approaches for immune checkpoint therapy. Nat Immunol. 2024;25:2186\u201399.","journal-title":"Nat Immunol"},{"key":"3801_CR4","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1601773","volume":"16","author":"FP Kraja","year":"2025","unstructured":"Kraja FP, Jurisic VB, Hromi\u0107-Jahjefendi\u0107 A, Rossopoulou N, Katsila T, Mirjacic Martinovic K, et al. Tumor-infiltrating lymphocytes in cancer immunotherapy: from chemotactic recruitment to translational modeling. Front Immunol. 2025;16:1601773.","journal-title":"Front Immunol"},{"key":"3801_CR5","first-page":"1","volume":"17","author":"NR Maimela","year":"2018","unstructured":"Maimela NR, Liu S, Zhang Y. Fates of CD8+ T cells in tumor microenvironment. Comput Struct Biotechnol J. 2018;17:1\u201313.","journal-title":"Comput Struct Biotechnol J"},{"key":"3801_CR6","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-020-01234-1","volume":"19","author":"C Li","year":"2020","unstructured":"Li C, Jiang P, Wei S, Xu X, Wang J. Regulatory t cells in tumor microenvironment: new mechanisms, potential therapeutic strategies and future prospects. Mol Cancer. 2020;19:116.","journal-title":"Mol Cancer"},{"key":"3801_CR7","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1016\/j.immuni.2024.02.001","volume":"57","author":"AN Shouse","year":"2024","unstructured":"Shouse AN, LaPorte KM, Malek TR. Interleukin-2 signaling in the regulation of T cell biology in autoimmunity and cancer. Immunity. 2024;57:414\u201328.","journal-title":"Immunity"},{"key":"3801_CR8","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1038\/s41586-021-03861-0","volume":"597","author":"F Mo","year":"2021","unstructured":"Mo F, Yu Z, Li P, Oh J, Spolski R, Zhao L, et al. Leonard, an engineered IL-2 partial agonist promotes CD8+ T cell stemness. Nature. 2021;597:544\u20138.","journal-title":"Nature"},{"key":"3801_CR9","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1016\/S0065-2776(04)86006-1","volume":"86","author":"B Becknell","year":"2005","unstructured":"Becknell B, Caligiuri MA. Interleukin-2, interleukin-15, and their roles in human natural killer cells. Adv Immunol. 2005;86:209\u201339.","journal-title":"Adv Immunol"},{"key":"3801_CR10","doi-asserted-by":"publisher","first-page":"7826","DOI":"10.7150\/thno.37216","volume":"9","author":"J Zhuang","year":"2019","unstructured":"Zhuang J, Holay M, Park JH, Fang RH, Zhang J, Zhang L. Nanoparticle delivery of immunostimulatory agents for cancer immunotherapy. Theranostics. 2019;9:7826\u201348.","journal-title":"Theranostics"},{"key":"3801_CR11","doi-asserted-by":"crossref","unstructured":"Staedtke V, Bai R, Sun N. Hypoxia-targeting bacteria in cancer therapy. Semin. Cancer Biol. 2024;100:39\u201348.","DOI":"10.1016\/j.semcancer.2024.03.003"},{"key":"3801_CR12","doi-asserted-by":"publisher","first-page":"3553","DOI":"10.1038\/s41467-023-39224-8","volume":"14","author":"R Salama","year":"2023","unstructured":"Salama R, Sharma P, Thapa B, Wilson R, Barczak C, Guo J, Zhang Y. Bioengineering of bacteria for cancer immunotherapy. Nat Commun. 2023;14:3553.","journal-title":"Nat Commun"},{"key":"3801_CR13","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-023-39365-2","volume":"13","author":"S Tumas","year":"2023","unstructured":"Tumas S, Meldgaard TS, Vaaben TH, Suarez Hernandez S, Rasmussen AT, Vazquez-Uribe R, et al. Engineered Escherichia coli Nissle 1917 for delivery of bioactive IL-2 for cancer immunotherapy. Sci Rep. 2023;13:12506.","journal-title":"Sci Rep"},{"key":"3801_CR14","volume":"14","author":"E G\u00fcl","year":"2024","unstructured":"G\u00fcl E, Aydin A, Cansu A, Korkmaz H, Ers\u00f6zl\u00fc A, Aksoy E. Attenuated Salmonella typhimurium L-forms suppress tumor growth and enhance antitumor immune responses in epithelial ovarian cancer models. Sci Rep. 2024;14:12092.","journal-title":"Sci Rep"},{"key":"3801_CR15","doi-asserted-by":"publisher","first-page":"1311","DOI":"10.1038\/s41587-024-02418-6","volume":"43","author":"S Yang","year":"2025","unstructured":"Yang S, Sheffer M, Kaplan IE, Wang Z, Tarannum M, Dinh K, Abdulhamid Y, Bobilev E, Shapiro R, Porter R, Soiffer R, Ritz J, Wei Y, Chen P, Zhang K, M\u00e1rquez-Pellegrin V, Bonanno S, Joshi N, Guan M, Yang M, Li D, Bellini C, Koreth J, Wu CJ, Barbie D. Non-pathogenic E. coli displaying decoy-resistant IL-18 Mutein boosts anti-tumor and CAR NK cell responses. Nat Biotechnol. 2025;43:1311\u201323.","journal-title":"Nat Biotechnol"},{"key":"3801_CR16","doi-asserted-by":"publisher","DOI":"10.1016\/j.biomaterials.2021.121257","volume":"280","author":"J Kim","year":"2022","unstructured":"Kim J, Kang S, Kim KW, Heo MG, Park DI, Lee JH, et al. Nanoparticle delivery of recombinant IL-2 (BALLkine-2) achieves durable tumor control with less systemic adverse effects in cancer immunotherapy. Biomaterials. 2022;280:121257.","journal-title":"Biomaterials"},{"key":"3801_CR17","doi-asserted-by":"publisher","DOI":"10.1002\/adhm.202202870","volume":"12","author":"NA Siddiqui","year":"2023","unstructured":"Siddiqui NA, Ventrola AJ, Hartman AR, Konare T, Kamble NS, Thomas SC, et al. An engineered probiotic platform for cancer epitope-independent targeted radionuclide therapy of solid tumors. Adv Healthc Mater. 2023;12:2202870.","journal-title":"Adv Healthc Mater"},{"key":"3801_CR18","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1038\/bjc.1988.231","volume":"58","author":"AMM Eggermont","year":"1988","unstructured":"Eggermont AMM, Sugarbaker PH. Efficacy of chemoimmunotherapy with cyclophosphamide, interleukin-2 and lymphokine activated killer cells in an intraperitoneal murine tumour model. Br J Cancer. 1988;58:410\u20134.","journal-title":"Br J Cancer"},{"key":"3801_CR19","doi-asserted-by":"publisher","DOI":"10.1016\/j.jep.2023.116533","volume":"313","author":"J Yao","year":"2023","unstructured":"Yao J, Liu J, He Y, Liu L, Xu Z, Lin X, et al. Systems pharmacology reveals the mechanism of Astragaloside IV in improving immune activity on cyclophosphamide-induced immunosuppressed mice. J Ethnopharmacol. 2023;313:116533.","journal-title":"J Ethnopharmacol"},{"key":"3801_CR20","doi-asserted-by":"publisher","first-page":"4384","DOI":"10.1182\/blood-2009-11-251231","volume":"115","author":"T Nakahara","year":"2010","unstructured":"Nakahara T, Uchi H, Lesokhin AM, Avogadri F, Rizzuto GA, Hirschhorn-Cymerman D, et al. Cyclophosphamide enhances immunity by modulating the balance of dendritic cell subsets in lymphoid organs. Blood. 2010;115:4384\u201392.","journal-title":"Blood"},{"key":"3801_CR21","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1007\/s00262-006-0225-8","volume":"56","author":"F Ghiringhelli","year":"2007","unstructured":"Ghiringhelli F, Menard C, Puig PE, Ladoire S, Roux S, Martin F, et al. Metronomic cyclophosphamide regimen selectively depletes CD4+CD25+ regulatory T cells and restores T and NK effector functions in end-stage cancer patients. Cancer Immunol Immunother. 2007;56:641\u20138.","journal-title":"Cancer Immunol Immunother"},{"key":"3801_CR22","first-page":"1736","volume":"18","author":"Y Ge","year":"2012","unstructured":"Ge Y, Domschke C, Stoiber N, Schott S, Heil J, Rom J, Blumenstein M, Thum J, Sohn C, Schneeweiss A, Schuetz F. Low-dose cyclophosphamide modulates immunity by affecting regulatory T cells in breast cancer patients: a phase I trial, clin. Cancer Res. 2012;18:1736\u201344.","journal-title":"Cancer Res"},{"key":"3801_CR23","first-page":"7039","volume":"15","author":"LA Emens","year":"2009","unstructured":"Emens LA, Asquith JM, Leatherman JM, Kobrin BJ, Petrik S, Laiko M, Levi J, Jaffee EM, Timmins L, Armstrong D. Low-dose cyclophosphamide combined with an allogeneic granulocyte\u2013macrophage colony-stimulating factor\u2013secreting breast tumor vaccine is safe and enhances immunity in patients with metastatic breast cancer. Clin Cancer Res. 2009;15:7039\u201347.","journal-title":"Clin Cancer Res"},{"key":"3801_CR24","first-page":"5990","volume":"47","author":"M Awwad","year":"1987","unstructured":"Awwad M, North RJ. Cyclophosphamide-induced immunologically mediated regression of a cyclophosphamide-resistant murine tumor: a consequence of eliminating precursor T regulatory cells. Cancer Res. 1987;47:5990\u20134.","journal-title":"Cancer Res"},{"key":"3801_CR25","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1007\/s00262-013-1397-7","volume":"62","author":"C Camisaschi","year":"2013","unstructured":"Camisaschi C, Filipazzi P, Tazzari M, Casati C, Beretta V, Pilla L, et al. Effects of cyclophosphamide and IL-2 on regulatory CD4+ T cell frequency and function in melanoma patients vaccinated with HLA-class I peptides: impact on the antigen-specific T cell response. Cancer Immunol Immunother. 2013;62:897\u2013908.","journal-title":"Cancer Immunol Immunother"},{"key":"3801_CR26","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1038\/nri3156","volume":"12","author":"O Boyman","year":"2012","unstructured":"Boyman O, Sprent J. The role of interleukin-2 during homeostasis and activation of the immune system. Nat Rev Immunol. 2012;12:180\u201390.","journal-title":"Nat Rev Immunol"},{"key":"3801_CR27","doi-asserted-by":"publisher","first-page":"944","DOI":"10.1016\/j.trecan.2022.06.008","volume":"8","author":"F Shan","year":"2022","unstructured":"Shan F, Somasundaram A, Bruno TC, Workman CJ, Vignali DAA. Therapeutic targeting of regulatory T cells in cancer. Trends Cancer. 2022;8:944\u201361.","journal-title":"Trends Cancer"},{"key":"3801_CR28","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1007\/s00281-011-0245-0","volume":"33","author":"A Sistigu","year":"2011","unstructured":"Sistigu A, Viaud S, Chaput N, Bracci L, Proietti E, Zitvogel L. Immunomodulatory effects of cyclophosphamide and implementations for vaccine design. Semin Immunopathol. 2011;33:369\u201382.","journal-title":"Semin Immunopathol"},{"key":"3801_CR29","doi-asserted-by":"publisher","first-page":"768","DOI":"10.1158\/0008-5472.CAN-10-2788","volume":"71","author":"G Schiavoni","year":"2011","unstructured":"Schiavoni G, Sistigu A, Valentini M, Mattei F, Sestili P, Spadaro F, Sanchez M, Lorenzi S, D\u2019Urso MT, Belardelli F, Gabriele L, Proietti E, Bracci L. Cyclophosphamide synergizes with type I interferons through systemic dendritic cell reactivation and induction of Immunogenic tumor apoptosis. Cancer Res. 2011;71:768\u201378.","journal-title":"Cancer Res"},{"key":"3801_CR30","doi-asserted-by":"publisher","DOI":"10.1016\/j.imbio.2022.152212","volume":"227","author":"F Tang","year":"2022","unstructured":"Tang F, Zhong Q, Yang Z, Li H, Pan C, Huang L, et al. Low-dose cyclophosphamide combined with IL-2 inhibits tumor growth by decreasing regulatory T cells and increasing CD8+ T cells and natural killer cells in mice. Immunobiology. 2022;227:152212.","journal-title":"Immunobiology"},{"key":"3801_CR31","first-page":"3689","volume":"61","author":"JP Machiels","year":"2001","unstructured":"Machiels JP, Reilly RT, Emens LA, Ercolini AM, Lei RY, Weintraub D, et al. Cyclophosphamide, doxorubicin, and Paclitaxel enhance the antitumor immune response of granulocyte\u2013macrophage colony-stimulating factor\u2013secreting whole-cell vaccines in HER-2\/neu mice. Cancer Res. 2001;61:3689\u201397.","journal-title":"Cancer Res"},{"key":"3801_CR32","doi-asserted-by":"publisher","first-page":"2862","DOI":"10.1182\/blood-2004-06-2410","volume":"105","author":"ME Lutsiak","year":"2005","unstructured":"Lutsiak ME, Semnani RT, De Pascalis R, Kashmiri SV, Schlom J, Sabzevari H. Inhibition of CD4+ 25+ T regulatory cell function implicated in enhanced immune response by low-dose cyclophosphamide. Blood. 2005;105:2862\u20138.","journal-title":"Blood"},{"key":"3801_CR33","doi-asserted-by":"crossref","unstructured":"Salgado R, Denkert C, Demaria S, Sirtaine N, Klauschen F, Pruneri G, Wienert S, Van den Eynden G, Baehner FL, Penault-Llorca F, Perez EA, Thompson EA, Symmans WF, Richardson AL, Brock J, Criscitiello C, Bailey H, Ignatiadis M, Floris G, Sparano J, Kos Z, Nielsen T, Rimm DL, Allison KH, Reis-Filho JS, Loibl S, Sotiriou C, Viale G, Badve S, Adams S, Willard-Gallo K, Loi S. The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014, Ann. Oncol., 26 (2015) 259\u2013271.","DOI":"10.1093\/annonc\/mdu450"},{"key":"3801_CR34","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1038\/s41416-022-02119-4","volume":"128","author":"K Brummel","year":"2023","unstructured":"Brummel K, Eerkens AL, de Bruyn M, Nijman HW. Tumour-infiltrating lymphocytes: from prognosis to treatment selection. Br J Cancer. 2023;128:451\u20138.","journal-title":"Br J Cancer"},{"key":"3801_CR35","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1038\/s41568-021-00339-z","volume":"21","author":"S Jhunjhunwala","year":"2021","unstructured":"Jhunjhunwala S, Hammer C, Delamarre L. Antigen presentation in cancer: insights into tumour immunogenicity and immune evasion. Nat Rev Cancer. 2021;21:298\u2013312.","journal-title":"Nat Rev Cancer"},{"key":"3801_CR36","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1038\/s41577-018-0046-y","volume":"18","author":"R Spolski","year":"2018","unstructured":"Spolski R, Li P, Leonard WJ. Biology and regulation of IL-2: from molecular mechanisms to human therapy. Nat Rev Immunol. 2018;18:648\u201359.","journal-title":"Nat Rev Immunol"},{"key":"3801_CR37","doi-asserted-by":"publisher","DOI":"10.1002\/adma.202207198","volume":"35","author":"X Zhu","year":"2023","unstructured":"Zhu X, Chen S, Hu X, Zhao L, Wang Y, Huang J, et al. Near-infrared nano-optogenetic activation of cancer immunotherapy via engineered bacteria. Adv Mater. 2023;35:2207198.","journal-title":"Adv Mater"},{"key":"3801_CR38","doi-asserted-by":"publisher","first-page":"4933","DOI":"10.7150\/thno.98097","volume":"14","author":"X Hu","year":"2024","unstructured":"Hu X, Chen J, Qiu Y, Chen S, Liu Y, Yu X, et al. Bacteria-based cascade near-infrared nano-optogenetically induced photothermal tumor therapy. Theranostics. 2024;14:4933\u201347.","journal-title":"Theranostics"}],"container-title":["Journal of Nanobiotechnology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12951-025-03801-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12951-025-03801-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12951-025-03801-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,3]],"date-time":"2026-01-03T19:04:23Z","timestamp":1767467063000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12951-025-03801-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,28]]},"references-count":38,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["3801"],"URL":"https:\/\/doi.org\/10.1186\/s12951-025-03801-4","relation":{},"ISSN":["1477-3155"],"issn-type":[{"value":"1477-3155","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,28]]},"assertion":[{"value":"30 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All animal studies were approved by the Institutional Animal Care and Use Committee of Huazhong University of Science and Technology (IACUC Number: 4142).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All authors of this study agreed to publish.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"5"}}